Reviva Pharmaceuticals Launches Enrollment of Patients in RP5063 Phase 2 Trial

The Phase 2 study is to assess the efficacy, safety and tolerability of RP5063 in male and female patients with schizophrenia.

Reviva Pharmaceuticals, Inc. announced Monday enrollment of patients in its phase 2 clinical study of RP503 for schizophrenia and schizoaffective disorder.

The purpose of this randomized, double-blind, placebo-controlled, four-arm, global multi-center Phase 2 study is to assess the efficacy, safety and tolerability of RP5063 in male and female patients with schizophrenia.

The trial plans to enroll 228 patients from USA, India, Philippines, Malaysia and Russia. The company expects to report results of this Phase 2 clinical study for RP5063 towards the end of this year.

Results from the Phase 1 clinical study of RP5063 conducted in the United Stat